Published: 09/02/2009 - PDF Version (90 KB)
CHIPing away at cancer metastasis
Scientists have discovered that an enzyme called CHIP suppresses breast cancer. The research, published online in Nature Cell Biology, suggests that a target of the enzyme known as SRC-3 represents a promising new molecular target for this cancer.
Many solid tumours form metastases, where the cancer spreads from its site of origin – this is the main reason for therapeutic failure and cancer mortality. As such, there is a renewed focus on designing drugs that target molecular pathways required for metastasis.
Junn Yanagisawa, from the University of Tsukuba, Japan, and colleagues report that CHIP, which is known to degrade a number of cancer causing proteins, also acts to degrade the gene regulator SRC-3, which then suppresses tumour progression in breast cancer. In a mouse model, CHIP expression inhibited metastasis formation, while its deletion accelerated the process. Loss of CHIP leads to increased expression of a number of cancer associated proteins, causing cells to become invasive and to grow in an uncontrolled manner, both attributes of cancer cells.
Since SRC-3 accounts for the cancer suppressive role of CHIP, it presents a new therapeutic target for breast cancer.
Article DOI: 10.1038/ncb1839
No comments have been posted yet. Post a comment.

Intensive chemotherapy may be harmful to most older patients with AML
New molecular marker could predict if breast cancer patients need chemotherapy
CTC screening for colorectal cancer not cost-effective when reimbursed at same rate as colonoscopy
Women in their forties have lower mammographic tumour detectability
Genetic risk score associated with breast cancer risk
New roundtable debate: communicating risk in familial cancer
Study finds that the GRB7 gene drives an aggressive form of the disease
ASCO updates guideline on adjuvant hormonal therapy for breast cancer
NICE guideline set to improve care of cancer patients with unknown primary